Regeneron Pharmaceuticals reported a 72.5% fall in quarterly profit on Wednesday, hurt by lackluster sales of its COVID-19 antibody cocktail after the U.S. health regulator decided to limit its use earlier this year.
The company recorded no sales from the COVID-19 antibody in the United States for the second consecutive quarter.
Regeneron had warned of no U.S. sales from the drug in the first half of the year after the U.S. regulator banned it, with some exceptions, in all states due to its lack of effectiveness against the Omicron coronavirus variant.
Second-quarter revenue fell to $2.86 billion from $5.14 billion a year ago.
The drugmaker's net profit fell to $852 million, or $7.47 per share, in the second quarter ended June 30, compared with $3.1 billion, or $27.97 per share, a year earlier.
© 2026 Thomson/Reuters. All rights reserved.